Top Stories
FDA grants accelerated approval to Denali's AVLAYAH for neurologic manifestations of Hunter syndrome, first CNS-penetrant ERT in MPS II
The FDA granted accelerated approval on March 25, 2026 to AVLAYAH (tividenofusp alfa-eknm), Denali Therapeutics' enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II), per the Denali Therapeutics press release. The accelerated approval was based on a surrogate endpoint — reduction of cerebrospinal fluid heparan sulfate — which FDA determined was reasonably likely to predict clinical benefit; continued approval may be contingent on a confirmatory trial. STAT News reported the approval is particularly meaningful in the current regulatory environment, where orphan drug applications have faced increased scrutiny. AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier via the transferrin receptor, addressing CNS penetration — a persistent challenge in MPS II where neurological involvement limits the benefit of existing intravenous ERTs. It is the first new approved treatment for Hunter syndrome in nearly 20 years. Hunter syndrome is an X-linked lysosomal storage disorder affecting predominantly males, caused by deficiency of the iduronate-2-sulfatase enzyme, leading to progressive multisystem deterioration. Pricing and reimbursement terms had not been publicly disclosed as of this digest.
Sarepta first-in-human siRNA data for FSHD1 and DM1 signal muscle uptake without dose-limiting toxicity
Sarepta Therapeutics disclosed initial clinical findings from two siRNA programs targeting facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1), representing the first human data from the company's 2024 licensing agreement with Arrowhead Pharmaceuticals. Per Sarepta investor relations, the integrin-targeted delivery approach achieved high muscle tissue concentrations without dose-limiting toxicity in early cohorts. BioPharma Dive reported that the data represent an early validation of the company's strategic pivot toward RNA therapeutics as it navigates ongoing uncertainty around its ELEVIDYS gene therapy franchise. Endpoints News noted that Sarepta framed the results as a rebound signal following a turbulent period marked by regulatory and commercial setbacks in the Duchenne program. FSHD1 and DM1 are both commercially meaningful orphan populations with no approved disease-modifying therapies. The data are Phase 1 in nature and do not yet include functional endpoints or durability observations; efficacy conclusions would be premature at this stage. Upcoming dose-escalation cohorts and biomarker readouts will be the key catalysts to determine whether muscle concentration translates to target engagement and functional benefit.
Ocugen advances to Phase 3 in geographic atrophy gene therapy after Phase 2 meets primary targets with mixed investor reaction
Ocugen announced it will advance OCU400 into a Phase 3 trial for geographic atrophy (GA), a late-stage manifestation of dry age-related macular degeneration, following 12-month Phase 2 data that met primary lesion-reduction endpoints but drew a cautious market response. As Endpoints News reported, the company cited the full Phase 2 win as the basis for proceeding to a registrational study. Fierce Biotech noted that while the therapy significantly reduced lesion size at 12 months, the observed effect size appeared smaller relative to earlier interim data, which contributed to investor skepticism despite the technical endpoint achievement. Geographic atrophy is a common condition (not classified as a rare disease), though the subset eligible for gene therapy will depend on disease stage criteria and competitive positioning against anti-complement biologics already approved in this indication. Note: GA is included in this digest based on gene therapy modality relevance. The Phase 3 design, patient selection criteria, and primary endpoint choice will be closely scrutinized given the mixed Phase 2 signal and the need to demonstrate a clinically meaningful benefit threshold acceptable to FDA. Ocugen has not disclosed a Phase 3 timeline or enrollment targets as of this writing. The program also raises broader questions about the durability of single-administration gene therapy in a slowly progressive retinal disease where long-term follow-up data will be essential for payer acceptance.
Pipeline Watch
Beam Therapeutics announced on March 25, 2026 that updated Phase 1/2 data for BEAM-302, a first-in-class base editing gene therapy for alpha-1 antitrypsin deficiency (AATD), support advancement to pivotal development in H2 2026, per the Beam Therapeutics press release. After a single 60 mg dose, 94% of circulating AAT was correctly folded, with mean steady-state total AAT levels of 16.1 µM — above the 11 µM protective threshold — maintained for up to 12 months. BioSpace characterized the data as "impressive" and noted the 60 mg dose was selected for pivotal. Beam intends to pursue accelerated approval based on AAT biomarker endpoints at 12 months, enrolling approximately 50 additional AATD patients with lung disease. AATD is a rare genetic disorder affecting an estimated 60,000 to 100,000 individuals in the US, though the majority remain undiagnosed. Safety data from 26 patients showed a well-tolerated profile with no serious adverse events or dose-limiting toxicities. This represents the first clinical demonstration of genetic correction of a disease-causing mutation via base editing.
Ionis Pharmaceuticals announced a reduction in the wholesale acquisition cost of Tryngolza (olezarsen) from $595,000/yr to $40,000/yr effective April 1, 2026, a 93% price cut, per the Ionis press release. Tryngolza is currently approved for familial chylomicronemia syndrome (FCS), an ultra-rare lipid disorder. The repricing is timed ahead of a Priority Review sPLDA for label expansion into severe hypertriglyceridemia (sHTG), with a PDUFA target action date of June 30, 2026. Fierce Pharma reported the move signals Ionis's intent to position the drug competitively for the much larger sHTG market. The new WAC will apply across both FCS and sHTG indications. This is among the largest single price reductions for an approved rare disease drug and may set a precedent for how sponsors reprice orphan drugs ahead of label expansions into broader populations.
Scotland launched a two-year national pilot to screen all newborns for spinal muscular atrophy (SMA) as part of the NHS blood spot test, becoming the first UK nation to do so, according to Muscular Dystrophy UK. The pilot, funded by the Scottish Government and Novartis, screens approximately 45,000 babies per year. The Conversation noted that presymptomatic diagnosis is clinically meaningful because early treatment initiation — particularly with Novartis's gene therapy Zolgensma (onasemnogene abeparvovec) or Biogen's Spinraza (nusinersen) — can prevent irreversible motor neuron loss. SMA affects approximately 3 to 4 newborns per year in Scotland and roughly 70 across the UK. The program may serve as a model for other UK nations and EU member states evaluating SMA newborn screening, with direct implications for gene therapy utilization rates and the commercial uptake of Zolgensma in presymptomatic populations.
Immutrin closed an $87 million financing round to advance its lead program targeting a progressive rare cardiac condition, per BioPharma Dive. Specific disease indication, mechanism of action, and trial timelines were not fully detailed in public disclosures at the time of this digest.
Alnylam management articulated a path for Amvuttra (vutrisiran) to achieve revenue leadership in ATTR cardiomyopathy, according to Fierce Pharma. ATTR-CM is increasingly contested across RNAi, antisense, and small molecule modalities, and Alnylam's ability to defend Amvuttra's position will hinge on outcomes data, label differentiation, and payer contracting.
Competitive Landscape
Sarepta's early siRNA data in FSHD1 and DM1 place it among a small number of developers pursuing RNA-based disease modification in these indications. Both conditions lack approved therapies targeting the underlying mechanism, which creates an open competitive field but also a high evidentiary bar for regulators and payers accustomed to limited natural history data.
| Company | Modality | Indication | Stage |
|---|---|---|---|
| Sarepta / Arrowhead | siRNA (integrin-targeted) | FSHD1 | Phase 1 |
| Sarepta / Arrowhead | siRNA (integrin-targeted) | DM1 | Phase 1 |
| No approved agent | N/A | FSHD1 | No approved therapy |
| No approved agent | N/A | DM1 | No approved therapy |
With Alnylam publicly addressing market leadership questions for Amvuttra in ATTR-CM, the indication is emerging as one of the most contested spaces in rare cardiovascular disease. RNAi, antisense oligonucleotide, and small molecule stabilizer approaches are all active, raising questions about how payers will structure formulary access and outcomes-based contracts across competing agents.
| Company | Agent | Modality | ATTR-CM Status |
|---|---|---|---|
| Alnylam | Amvuttra (vutrisiran) | RNAi | Approved |
| Ionis / AstraZeneca | Eplontersen (WAINUA) | ASO | Approved ATTR-PN (Dec 2023); ATTR-CM sNDA under review |
| Pfizer | Tafamidis | Small Molecule Stabilizer | Approved |
| BridgeBio | Acoramidis | Small Molecule Stabilizer | Approved |
Ocugen's Phase 3 entry into GA occurs after Apellis and Astellas received approvals for intravitreal complement inhibitors in the same indication. A gene therapy entrant will need to demonstrate a differentiated efficacy profile or administration convenience advantage to justify its position, particularly given one-time dosing economics versus chronic biologic administration.
Hunter syndrome has had intravenous ERT available for over a decade, but CNS penetration remains an unresolved limitation. AVLAYAH's accelerated approval for neurologic manifestations, based on CSF heparan sulfate reduction as a surrogate endpoint, may redefine the treatment standard for patients with neurocognitive involvement if confirmatory data demonstrate clinical benefit.
Forward Looking
- Beam Therapeutics plans to initiate its BEAM-302 pivotal cohort in H2 2026, pursuing accelerated approval for AATD based on AAT biomarker endpoints at 12 months with approximately 50 additional patients; pivotal enrollment timing and site activation will be key milestones.
- Ionis faces a June 30, 2026 PDUFA date for Tryngolza's sHTG label expansion under Priority Review; an approval would test whether the $40,000/yr WAC drives rapid uptake in a much larger severe hypertriglyceridemia population.
- Scotland's two-year SMA newborn screening pilot may influence screening policy decisions across the rest of the UK and EU; early data on presymptomatic diagnosis rates and gene therapy utilization will be watched by Novartis and Biogen.
- Denali AVLAYAH pricing and label details for Hunter syndrome remain undisclosed; as an accelerated approval, the confirmatory trial design and timeline will be closely scrutinized.
- Sarepta siRNA dose-escalation cohorts and first functional biomarker readouts for FSHD1 and DM1 will determine whether early pharmacokinetic signals translate to target engagement and clinical benefit.
- Ocugen Phase 3 protocol design for geographic atrophy gene therapy, including primary endpoint selection and patient eligibility criteria, warrants attention given the attenuated effect size in Phase 2.
- Alnylam Amvuttra outcomes data timelines and payer contracting moves in ATTR-CM will be critical to monitor as multiple approved agents compete for formulary positioning.